hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
the following table provides a summary of our historical capital expenditures related to the upgrading of our infrastructure and systems: .

Table:
( in millions ) | for the years ended december 31 , 2018 | for the years ended december 31 , 2017 | for the years ended december 31 , 2016
transmission and distribution | $ 572 | $ 551 | $ 568
treatment and pumping | 231 | 171 | 151
services meter and fire hydrants | 303 | 281 | 297
general structure and equipment | 371 | 281 | 202
sources of supply | 26 | 54 | 59
wastewater | 83 | 96 | 34
total capital expenditures | $ 1586 | $ 1434 | $ 1311
in 2018 , our capital expenditures increased $ 152 million , or 10.6% ( 10.6 % ) , primarily due to investment across the majority of our infrastructure categories .
in 2017 , our capital expenditures increased $ 123 million , or 9.4% ( 9.4 % ) , primarily due to investment in our general structure and equipment and wastewater categories .
we also grow our business primarily through acquisitions of water and wastewater systems , as well as other water-related services .
these acquisitions are complementary to our existing business and support continued geographical diversification and growth of our operations .
generally , acquisitions are funded initially with short- term debt , and later refinanced with the proceeds from long-term debt .
the following is a summary of the acquisitions and dispositions affecting our cash flows from investing activities : 2022 the majority of cash paid for acquisitions pertained to the $ 365 million purchase of pivotal within our homeowner services group .
2022 paid $ 33 million for 15 water and wastewater systems , representing approximately 14000 customers .
2022 received $ 35 million for the sale of assets , including $ 27 million for the sale of the majority of the o&m contracts in our contract services group during the third quarter of 2018 .
2022 the majority of cash paid for acquisitions pertained to the $ 159 million purchase of the wastewater collection and treatment system assets of the municipal authority of the city of mckeesport , pennsylvania ( the 201cmckeesport system 201d ) , excluding a $ 5 million non-escrowed deposit made in 2016 .
2022 paid $ 18 million for 16 water and wastewater systems , excluding the mckeesport system and shorelands ( a stock-for-stock transaction ) , representing approximately 7000 customers .
2022 received $ 15 million for the sale of assets .
2022 paid $ 199 million for 15 water and wastewater systems , representing approximately 42000 customers .
2022 made a non-escrowed deposit of $ 5 million related to the mckeesport system acquisition .
2022 received $ 9 million for the sale of assets .
as previously noted , we expect to invest between $ 8.0 billion to $ 8.6 billion from 2019 to 2023 , with $ 7.3 billion of this range for infrastructure improvements in our regulated businesses .
in 2019 , we expect to .

Question: what percentage of total capital expenditures were related to transmission and distribution in 2018?
Answer: 36.1%
Calculation: divide(572, 1586)
Gross margin
The Group achieved further gross margin expansion in 2019 with an increase of 1.0 percentage points, to 73.2 per cent from 72.2 per cent in 2018. This followed an increase of 0.7 percentage points last year. Once again, all the operating segments achieved an improvement in gross margin, benefiting from new product launches and a higher proportion of software sales.
Table:
$ million | 2019 | % | 2018 | %
Networks & Security | 232.3 | 72.6 | 205.3 | 72.0
Lifecycle Service Assurance | 88.6 | 79.7 | 87.9 | 77.9
Connected Devices | 47.7 | 65.8 | 51.3 | 64.9
 | 368.6 | 73.2 | 344.5 | 72.2


Question: What was the change in the amount of gross profits?
Answer: 24.1
Calculation: 368.6-344.5
Subsequent to origination, the delinquency and write-off experience is monitored as key credit quality indicators for the portfolio of device payment plan agreement receivables and fixed-term service plans. The extent of collection efforts with respect to a particular customer are based on the results of proprietary custom empirically derived internal behavioral-scoring models that analyze the customer’s past performance to predict the likelihood of the customer falling further delinquent.
These customer-scoring models assess a number of variables, including origination characteristics, customer account history and payment patterns. Based on the score derived from these models, accounts are grouped by risk category to determine the collection strategy to be applied to such accounts.
Collection performance results and the credit quality of device payment plan agreement receivables are continuously monitored based on a variety of metrics, including aging. An account is considered to be delinquent and in default status if there are unpaid charges remaining on the account on the day after the bill’s due date.
At December 31, 2019 and 2018, the balance and aging of the device payment plan agreement receivables on a gross basis was as follows:
Table:
 | 2019 | 2018
Unbilled | $ 12,403 | $ 11,485
Billed: |  | 
Current | 815 | 641
Past due | 262 | 209
Device payment plan agreement receivables, gross | $ 13,480 | $ 12,335


Question: What is the increase / (decrease) in the unbilled from 2018 to 2019?
Answer: 918
Calculation: 12,403 - 11,485
Stock-Based Compensation
The following table summarizes the components of total stock-based compensation included in VMware’s consolidated statements of income during the periods presented (table in millions):
As of January 31, 2020, the total unrecognized compensation cost for stock options and restricted stock was $1.8 billion and will be recognized through fiscal 2024 with a weighted-average remaining period of 1.5 years. Stock-based compensation related to VMware equity awards held by VMware employees is recognized on VMware’s consolidated statements of income over the awards’ requisite service periods.
Table:
 |  | For the Year Ended | 
 | January 31, 2020 | February 1, 2019 | February 2, 2018
Cost of license revenue | $1 | $1 | $2
Cost of subscription and SaaS revenue | 13 | 7 | 5
Cost of services revenue | 83 | 58 | 53
Research and development | 459 | 391 | 363
Sales and marketing | 293 | 226 | 205
General and administrative | 168 | 117 | 84
Stock-based compensation | 1,017 | 800 | 712
Income tax benefit | (347) | (253) | (232)
Total stock-based compensation, net of tax | $670 | $547 | $480


Question: Which years did Stock-based compensation exceed $1,000 million?
Answer: 2020
Calculation: (2020:1,017)
Restricted Stock Units
Certain key employees have been granted time-based, performance-based and market-based restricted stock units. The time-based restricted stock units granted generally vest on a graded vesting schedule over three years. The performance-based restricted stock units generally vest on a cliff vesting schedule over three years and up to a maximum of 150%, depending on the specified performance condition and the level of achievement obtained. The performance-based restricted stock units have a vesting condition that is based upon the Company’s cumulative adjusted core earnings per share during the performance period. The market-based restricted stock units generally vest on a cliff vesting schedule over three years and up to a maximum of 200%, depending on the specified performance condition and the level of achievement obtained. The market-based restricted stock units have a vesting condition that is tied to the Company’s total shareholder return based on the Company’s stock performance in relation to the companies in the Standard and Poor’s (S&P) Super Composite Technology Hardware and Equipment Index excluding the Company.
On October 6, 2017, the Company’s Compensation Committee approved the modification of vesting criteria for certain performance-based restricted stock units granted in fiscal year 2015. As a result of the modification, 0.8 million awards vested during the first quarter of fiscal year 2018, which resulted in approximately $24.9 million of stock-based compensation expense recognized.
The following table summarizes restricted stock units activity from August 31, 2018 through August 31, 2019:
(1) For those shares granted that are based on the achievement of certain performance criteria, the amount represents the maximum number of shares that can vest. During the fiscal year ended August 31, 2019, the Company awarded approximately 1.6 million time-based restricted stock units, 0.4 million performance based restricted stock units and 0.4 million market-based restricted stock units based on target performance criteria.
Table:
 | Shares | Weighted- Average Grant-Date Fair Value
Outstanding as of August 31, 2018 | 8,352,307 | $24.34
Changes during the period |  | 
Shares granted(1) | 3,144,205 | $25.25
Shares vested | (1,983,411) | $25.07
Shares forfeited | (2,347,628) | $24.78
Outstanding as of August 31, 2019 | 7,165,473 | $26.27


Question: What was the change in the weighted average grant-date fair value between 2018 and 2019?
Answer: 1.93
Calculation: $26.27-$24.34
Item 10. Directors, Executive Officers and Corporate Governance.
Executive Officers and Directors
The following sets forth certain information with respect to our executive officers and directors..
Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus
Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan
Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and
pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of
research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of
Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits
to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine
Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology
Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr.
Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National
Laboratories in Long Island, NY. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as
years of expertise in the financial and biopharmaceutical arenas.
Table:
Name | Age | Position (s)
Garo H. Armen | 67 | Executive Chairman of the Board of Directors
Alexander K. Arrow | 49 | Chief Financial Officer
Robert B. Stein | 69 | Director
Khalil Barrage | 55 | Director
Brian J. Corvese | 62 | Director
Josh Silverman | 49 | Director


Question: What is the average age of the directors in the company?
Answer: 58.75
Calculation: (69 + 55 + 62 + 49)/4
equity compensation plan information the following table presents the equity securities available for issuance under our equity compensation plans as of december 31 , 2018 . equity compensation plan information plan category number of securities to be issued upon exercise of outstanding options , warrants and rights ( 1 ) weighted-average exercise price of outstanding options , warrants and rights number of securities remaining available for future issuance under equity compensation plans ( excluding securities reflected in column ( a ) ) ( a ) ( b ) ( c ) equity compensation plans approved by security holders 399165 $ 0.00 3995600 equity compensation plans not approved by security holders ( 2 ) 2014 2014 2014 .

Table:
plan category | number of securities to be issued upon exercise of outstanding options warrants and rights ( 1 ) ( a ) ( b ) | weighted-average exercise price of outstanding optionswarrants and rights | number of securities remaining available for future issuance under equity compensation plans ( excluding securitiesreflected in column ( a ) ) ( c )
equity compensation plans approved by security holders | 399165 | $ 0.00 | 3995600
equity compensation plans not approved by security holders ( 2 ) | 2014 | 2014 | 2014
total | 399165 | $ 0.00 | 3995600
( 1 ) includes grants made under the huntington ingalls industries , inc .
2012 long-term incentive stock plan ( the "2012 plan" ) , which was approved by our stockholders on may 2 , 2012 , and the huntington ingalls industries , inc .
2011 long-term incentive stock plan ( the "2011 plan" ) , which was approved by the sole stockholder of hii prior to its spin-off from northrop grumman corporation .
of these shares , 27123 were stock rights granted under the 2011 plan .
in addition , this number includes 31697 stock rights , 5051 restricted stock rights , and 335293 restricted performance stock rights granted under the 2012 plan , assuming target performance achievement .
( 2 ) there are no awards made under plans not approved by security holders .
item 13 .
certain relationships and related transactions , and director independence information as to certain relationships and related transactions and director independence will be incorporated herein by reference to the proxy statement for our 2019 annual meeting of stockholders , to be filed within 120 days after the end of the company 2019s fiscal year .
item 14 .
principal accountant fees and services information as to principal accountant fees and services will be incorporated herein by reference to the proxy statement for our 2019 annual meeting of stockholders , to be filed within 120 days after the end of the company 2019s fiscal year. .

Question: as of december 312018 what was the ratio of the equity compensation plans approved by security holders number of securities to be issued to the number of securities remaining available for future issuance
Answer: 0.1
Calculation: divide(399165, 3995600)
2.6 Taxes (continued)
1 Net deferred tax liabilities include net deferred tax assets of $2,195,000 (2018: $1,937,000) from the iMoney Group.
Recognition and measurement
Our income tax expense is the sum of current and deferred income tax expenses. Current income tax expense is calculated on accounting profit after adjusting for non-taxable and non-deductible items based on rules set by the tax authorities. Deferred income tax expense is calculated at the tax rates that are expected to apply to the period in which the deferred tax asset is realised or the deferred tax liability is settled. Both our current and deferred income tax expenses are calculated using tax rates that have been enacted or substantively enacted at reporting date.
Our current and deferred taxes are recognised as an expense in profit or loss, except when they relate to items that are directly recognised in other comprehensive income or equity. In this case, our current and deferred tax expenses are also recognised directly in other comprehensive income or equity.
We generally recognise deferred tax liabilities for all taxable temporary differences, except to the extent that the deferred tax liability arises from:
• the initial recognition of goodwill; and
• the initial recognition of an asset or liability in a transaction that is not a business combination and affects neither our accounting profit nor our taxable income at the time of the transaction.
For our investments in controlled entities and associated entities, recognition of deferred tax liabilities is required unless we are able to control the timing of our temporary difference reversal and it is probable that the temporary difference will not reverse.
Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carried forward unused tax losses and tax credits, can be utilised
Deferred tax assets and deferred tax liabilities are offset in the statement of financial position where they relate to income taxes levied by the same taxation authority and to the extent that we intend to settle our current tax assets and liabilities on a net basis.
Table:
 | CONSOLIDATED | 
 | 2019 $’000 | 2018 $’000
Deferred taxes |  | 
Deferred tax assets relate to the following: |  | 
Trade and other payables | 2,312 | 1,558
Provisions | 4,759 | 2,230
Property, Plant and Equipment | - | 1,680
ITAA 97 Section 40-880 business related costs | 92 | 105
Unrealised foreign exchange differences | 58 | 56
Unused tax losses | 4,837 | 4,665
Other | 13 | 114
Total deferred tax assets | 12,071 | 10,408
 |  | 
Deferred tax liabilities relate to following: |  | 
Trail commission asset | (34,168) | (31,253)
Property, Plant and Equipment | (581) | -
Development costs | (2,109) | (2,359)
Total deferred tax liabilities | (36,858) | (33,612)
Net deferred tax liabilities1 | (24,787) | (23,204)


Question: What is the total deferred tax assets in 2019?
Answer: 12,071
During the three months ended June 30, 2018, the Company adopted ASU 2016-18-Statement of Cash Flows: Restricted Cash. This standard requires that the statement of cash flows explain the change during the period in total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard has been applied using a retrospective transition method to each period presented. The adoption of this standard did not have a material impact on the Company's financial statements.
The following table summarizes the opening balance sheet adjustments related to the adoption of the New Revenue Standard, ASU 2016-01-Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, and ASU 2016-16-Intra-Entity Transfers of Assets Other Than Inventory (in millions):
Table:
 | Balance as of |  | Adjustments from |  | Balance as of
 | March 31, 2018 | ASC 606 | ASU 2016-01 | ASU 2016-16 | April 1, 2018
ASSETS |  |  |  |  | 
Accounts receivable, net | $563.7 | $340.1 | $— | $— | $903.8
Inventories | $476.2 | $(5.1) | $— | $— | $471.1
Other current assets | $119.8 | $17.2 | $— | $— | $137.0
Long-term deferred tax assets | $100.2 | $(23.1) | $— | $1,579.4 | $1,656.5
Other assets | $71.8 | $— | $— | $(24.1) | $47.7
LIABILITIES |  |  |  |  | 
Accrued liabilities | $229.6 | $404.2 | $— | $— | $633.8
Deferred income on shipments to distributors | $333.8 | $(333.8) | $— | $— | $—
Long-term deferred tax liability | $205.8 | $16.8 | $— | $(1.1) | $221.5
Other long-term liabilities | $240.9 | $— | $— | $(1.7) | $239.2
STOCKHOLDERS' EQUITY |  |  |  |  | 
Accumulated other comprehensive loss | $(17.6) | $— | $(1.7) | $— | $(19.3)
Retained earnings | $1,397.3 | $241.9 | $1.7 | $1,558.1 | $3,199.0


Question: How many liabilities had a balance on March 31, 2018 that exceeded $300 million?
Answer: 1
Calculation: Deferred income on shipments to distributors
12 . brokerage receivables and brokerage payables the company has receivables and payables for financial instruments sold to and purchased from brokers , dealers and customers , which arise in the ordinary course of business . citi is exposed to risk of loss from the inability of brokers , dealers or customers to pay for purchases or to deliver the financial instruments sold , in which case citi would have to sell or purchase the financial instruments at prevailing market prices . credit risk is reduced to the extent that an exchange or clearing organization acts as a counterparty to the transaction and replaces the broker , dealer or customer in question . citi seeks to protect itself from the risks associated with customer activities by requiring customers to maintain margin collateral in compliance with regulatory and internal guidelines . margin levels are monitored daily , and customers deposit additional collateral as required . where customers cannot meet collateral requirements , citi may liquidate sufficient underlying financial instruments to bring the customer into compliance with the required margin level . exposure to credit risk is impacted by market volatility , which may impair the ability of clients to satisfy their obligations to citi . credit limits are established and closely monitored for customers and for brokers and dealers engaged in forwards , futures and other transactions deemed to be credit sensitive . brokerage receivables and brokerage payables consisted of the following: .

Table:
in millions of dollars | december 31 , 2018 | december 31 , 2017
receivables from customers | $ 14415 | $ 19215
receivables from brokers dealers and clearing organizations | 21035 | 19169
total brokerage receivables ( 1 ) | $ 35450 | $ 38384
payables to customers | $ 40273 | $ 38741
payables to brokers dealers and clearing organizations | 24298 | 22601
total brokerage payables ( 1 ) | $ 64571 | $ 61342
total brokerage payables ( 1 ) $ 64571 $ 61342 ( 1 ) includes brokerage receivables and payables recorded by citi broker-dealer entities that are accounted for in accordance with the aicpa accounting guide for brokers and dealers in securities as codified in asc 940-320. .

Question: what percentage of total brokerage payables at december 31 , 2018 where receivables from customers?
Answer: 22%
Calculation: divide(14415, 64571)
The reconciliation of the United Kingdom statutory tax rate to the Company’s effective tax rate included in the accompanying consolidated statements of operations is as follows:
Although the Company’s parent entity is organized under Jersey law, our affairs are, and are intended to be, managed and controlled ongoing in the United Kingdom. Therefore, the Company is resident in the United Kingdom for tax purposes. The Company’s parent entity is domiciled in the United Kingdom and its earnings are subject to 19%, 19% and 20% statutory tax rate for the years ended March 31, 2019, 2018 and 2017, respectively.
The Company’s effective tax rate differs from the statutory rate each year primarily due to windfall tax benefits on equity award exercises, the valuation allowance maintained against the Company’s net deferred tax assets, the jurisdictional earnings mix, tax credits, withholding taxes, and other permanent differences primarily related to non-deductible expenses.
Table:
 |  | Year ended March 31,  | 
 | 2019 | 2018 | 2017
Tax at statutory rate | 19.0% | 19.0% | 20.0%
U.S. state taxes, net of federal | 31.1 | 14.1 | (1.0)
Foreign rate differential   | 26.3 | 36.8 | (39.3)
Meals and entertainment   | (11.4) | (3.1) | (7.4)
Branch income / loss   | (0.6) | 0.4 | 0.9
Share-based compensation | 172.3 | 105.3 | (4.0)
Foreign exchange   | — | — | (24.8)
Non-deductible interest expense   | — | — | (3.3)
Tax credits | 7.7 | 8.1 | 15.6
Unremitted earnings   | (3.8) | (1.2) | —
Change in valuation allowance   | (249.9) | (110.7) | 124.7
Deferred tax true-ups   | (3.5) | 8.4 | (12.4)
Tax reserves   | (4.9) | (21.5) | (117.7)
Provision to return   | (0.1) | 0.4 | (0.7)
Withholding taxes   | (2.6) | (3.5) | —
Other foreign taxes   | — | — | (6.7)
Non-deductible expenses   | (5.2) | (2.4) | (10.6)
Deferred tax rate change   | (6.3) | (77.8) | (1.3)
Acquisition related costs   | (7.6) | — | —
Other   | (0.5) | (0.2) | —
Effective Tax Rate   | (40.0)% | (27.9)% | (68.0)%


Question: Which country controls the company's affairs?
Answer: United Kingdom